ENvue Medical (FEED) EBITDA Margin (2014 - 2026)

ENvue Medical (FEED) has reported EBITDA Margin for 13 consecutive years, with 2290.38% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 148552.0% year-over-year to 2290.38% in Q2 2026; TTM through Jun 2026 was 1362.72%, a 101351.0% decrease from a year earlier, with the FY2025 full-year figure at 896.55%, down 75652.0% from the prior year.
• EBITDA Margin was 2290.38% for Q2 2026 at ENvue Medical, down from 568.3% in the prior quarter.
• Over five years, EBITDA Margin peaked at 1674.51% in Q4 2022 and troughed at 4748.08% in Q4 2025.
• A 5-year average of 578.32% and a median of 303.29% in 2023 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin soared 199838 bps in 2022 and tumbled 443952 bps in 2025, its largest moves.
• Over 5 years, EBITDA Margin stood at 1674.51% in 2022, then sank by 104 bps to 59.64% in 2023, then slumped by 417 bps to 308.56% in 2024, then plunged by 1439 bps to 4748.08% in 2025, then surged by 52 bps to 2290.38% in 2026.
• The last three EBITDA Margin figures came in at 2290.38% (Q2 2026), 568.3% (Q1 2026), and 4748.08% (Q4 2025), per Business Quant data.